Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Retained Earnings (2017 - 2026)

Cogent Biosciences' Retained Earnings history spans 10 years, with the latest figure at -$1.3 billion for Q1 2026.

  • Quarterly Retained Earnings fell 784124.39% to -$1.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.3 billion through Mar 2026, down 784124.39% year-over-year, with the annual reading at -$1.2 billion for FY2025, 265965.77% down from the prior year.
  • Retained Earnings came in at -$1.3 billion for Q1 2026, down from -$1.2 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $447000.0 in Q4 2024 to a low of -$1.3 billion in Q1 2026.
  • The 5-year median for Retained Earnings is -$371.6 million (2022), against an average of -$468.8 million.
  • Year-over-year, Retained Earnings surged 520.51% in 2025 and then plummeted 784124.39% in 2026.
  • Cogent Biosciences' Retained Earnings stood at -$104000.0 in 2022, then plummeted by 580307.69% to -$603.6 million in 2023, then soared by 100.07% to $447000.0 in 2024, then crashed by 265965.77% to -$1.2 billion in 2025, then fell by 8.19% to -$1.3 billion in 2026.
  • Per Business Quant, the three most recent readings for COGT's Retained Earnings are -$1.3 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025).